Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review

Abisror, Noémie; Mékinian, A.; Lavigne, Christian; Vandenhende, Marie-Anne; Soussan, Michaël; Fain, Olivier

doi:10.1016/j.autrev.2013.06.019

Cited by 117 publications

(84 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Good response was seen in 75% of this pooled cohort and prednisone could be tapered from 15 to 5 mg daily. 60 A series of 10 adult TA patients from our center has reported 100% response to TCZ after the fourth infusion. However, only two of these 10 patients maintained sustained remission following discontinuation of TCZ therapy after 6 months; the vast majority needed rescue therapy in view of relapse.…”

Section: Biological Therapy In Tamentioning

confidence: 99%

Childhood‐onset Takayasu arteritis: an update

et al. 2015

View full text Add to dashboard Cite

Childhood-onset Takayasu arteritis (c-TA) is a distinct subset affecting a wide age group, ranging from young infants to adolescents and it differs from adult TA in many aspects. There is scarcity of data on c-TA worldwide. The disease is classified using the European League Against Rheumatism/Pediatric Rheumatology International Trials Organization/Pediatric Rheumatology European Society criteria. The non-specific nature of presenting complaints and lack of appropriate biomarkers delay the early diagnosis of this illness and many children present with complications, which become irreversible once they set in. One of the largest cohorts of 40 children with c-TA from our center reports hypertension as the commonest presenting feature. Systemic symptoms like headache, fever and weight loss are also described. Assessment of disease in c-TA is done by correlating clinical features with raised inflammatory markers. Advanced imaging plays an important role in diagnosis. In c-TA, the role of magnetic resonance angiography is advocated, taking into consideration the enormous amount of radiation exposure with other modalities. Complications of c-TA include cardiovascular, pulmonary, neurological and those arising secondary to long-term steroid and immunosuppression therapy.

show abstract

Section: Biological Therapy In Tamentioning

confidence: 99%

Childhood‐onset Takayasu arteritis: an update

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The first report of IL-6R blockade in TA described a dramatic prolonged response, with reduction in aortic wall thickness and resolution of ischemic symptoms, suggesting a disease-modifying effect 13 . Subsequently, small case series have described the further use of tocilizumab, with 44 patients included in a metaanalysis 14 . At time of analysis, just over half these patients continued taking tocilizumab therapy.…”

Section: Interleukin 6 Targeting In Refractory Takayasu Arteritis: Sementioning

confidence: 99%

“…Among the remainder, one-third achieved disease remission, and tocilizumab was stopped. In 40% of cases, treatment was withdrawn in the face of persistent radiological progression or disease relapse, while 20% suffered intolerable side effects 14 .…”

Section: Interleukin 6 Targeting In Refractory Takayasu Arteritis: Sementioning

confidence: 99%

Interleukin 6 Targeting in Refractory Takayasu Arteritis: Serial Noninvasive Imaging is Mandatory to Monitor Efficacy

Youngstein

Mason

2013

J Rheumatol

View full text Add to dashboard Cite

“…Of all, 78% have radiological improvement and the 20% have adverse effects [36]. Abisror et al have collected all the abstracts and reported totally 44 TA patients treated with Tocilizumab [37]. To this largest review the clinical response was 75% and only 7 relapses were reported.…”

Section: Tocilizumabmentioning

confidence: 99%

The Efficacy of Tocilizumab for Takayasu Arteritis: Review of the Literatures

Yeşil¹,

Şahin²,

Işık³

et al. 2015

OJRA

View full text Add to dashboard Cite

Takayasu arteritis is a large vessel vasculitis of the young women with giant cells and granuloma formation. The diagnosis and management of the disease are really not so easy because of the insidious onset and the difficulties in assessment of disease activity. Nearly 60% of the patients are corticosteroid resistant or dependent and relapses are very frequent during taper of the dose [1]. The novel biologic agents as Anti-TNF, Rutiximab and Tocilizumab provide acceptable response rates with low toxicity. Herein, we reviewed the efficacy of Tocilizumab in Takayasu arteritis.

show abstract

Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review

Cited by 117 publications

References 20 publications

Childhood‐onset Takayasu arteritis: an update

Childhood‐onset Takayasu arteritis: an update

Interleukin 6 Targeting in Refractory Takayasu Arteritis: Serial Noninvasive Imaging is Mandatory to Monitor Efficacy

The Efficacy of Tocilizumab for Takayasu Arteritis: Review of the Literatures

Contact Info

Product

Resources

About